

## DETECTION OF ABSCESES WITH $^{51}\text{Cr}$ -LABELED LEUKOCYTES

Our laboratory recently reported its experience with a technique for concentrating in a short time leukocytes which by all measurable parameters are physiologically intact (1). With a consistent reproducible  $^{51}\text{Cr}$  tag, our original purpose was to apply this technique to the detection and delineation of abscesses, such as has been reported by Winkelman (2) and Deysine (3).

We created experimental properitoneal abscesses in rabbits by the implantation of pellets containing large numbers of *E. coli* and *Staph aureus* organisms. Twenty-five to 50  $\mu\text{Ci}$  of  $^{51}\text{Cr}$  were tagged to isolated  $10^8$  WBC and injected into an ear vein. Images were performed at varying intervals from 15 min to 4 days. In eight rabbits so treated, we were unable to visualize the clinically obvious abscess satisfactorily by rectilinear scanning or by Anger camera scintigraphy.

In all our images the majority of radioactivity was present within the reticuloendothelial system. Liver, spleen, and bone marrow images were distinct. In addition, we have been consistently impressed by a high degree of activity in the lungs. Microscopic examination of our white cell preparations gave no indication that the white cell concentrates would be treated as microemboli.

Although we previously judged that a minimum of 3–5  $\mu\text{Ci}$  of  $^{51}\text{Cr}$  should be concentrated in a lesion before detection, it is evident that the reticuloendothelial activity of labeled leukocytes clearly exceeds the activity within the experimentally produced abscess.

Despite extensive characterization of a  $^{51}\text{Cr}$  label of an excellent white cell concentration, we have been unable to confirm the results of Winkelman and Deysine in the clinical definition of abscesses.

WILLIAM C. HARVEY  
JOSEPH SILVA  
Wilford Hall USAF Medical Center (AFSC)  
Lackland AFB, Texas

### REFERENCES

1. HARVEY WC, SILVA J:  $^{51}\text{Cr}$  labeling of concentrated phagocytes. *J Nucl Med* 14: 890–894, 1973
2. WINKELMAN J, COLLIKA CJ, SANDLER SG: The delineation of abscesses by scintiphotography using  $^{51}\text{Cr}$ -labeled leukocytes. *Am J Roentgenol Radium Ther Nucl Med* 103: 881–885, 1968
3. DEYSINE M, ROBINSON RG, WILDER JR: Abscess detection by radioactive chromium labeled autologous white blood cells. *Surg Gynecol Obstet* 131: 216–220, 1970

## SAFETY OF $^{169}\text{Yb}$ -DTPA IN CISTERNOGRAPHY

Barbizet, et al (1) have questioned the safety of  $^{169}\text{Yb}$ -DTPA as a cisternographic agent and have suggested that for 500  $\mu\text{Ci}$  of  $^{169}\text{Yb}$ -DTPA administered intrathecally, the radiation dose to the central nervous system (CNS) may be as high as 750 rads. Since no quantitative data are offered by the authors, it is very difficult to ascertain the basis for their conclusions which appear to be founded on subjective interpretations of images and it is equally difficult to determine how this type of data could be applied to dosimetry calculations. DeLand (2) demonstrated the distribution and quantity of residual  $^{169}\text{Yb}$ -DTPA following intrathecal administration. From data based on total-body imaging with computer analysis of distribution there was less than 4% retention within the CNS 14 days after administration. The retention of  $^{169}\text{Yb}$ -DTPA in dogs was found to correlate very closely with the excretion

rates of  $^{169}\text{Yb}$ -DTPA in man previously published by Wagner, et al (3) and with data obtained in this laboratory. Residual activity, most of which is fixed to brain tissue, does remain within the central nervous system. The quantity, however, is extremely small (2). The retention of  $^{169}\text{YbCl}_3$  (fixed to CNS tissue) is extremely high (2) and the possibility that the material used by Barbizet, et al contained  $^{169}\text{YbCl}_3$  must be considered. Our studies have indicated that Yb-DTPA is rapidly absorbed throughout the central nervous system so that even in cases of CNS block, retention should not be a serious problem.

To document the long-term elimination of  $^{169}\text{Yb}$ -DTPA in cisternography, we quantitatively restudied five patients who had been injected from 9 to 87 days before this examination (Table 1). All counting was performed for 5 min with a gamma camera (Nuclear-

TABLE 1. SUMMARY OF PATIENT DATA

Patient	Cisternographic findings	Time following injection (days)	$^{169}\text{Yb}$ -DTPA injected (mCi)	$^{169}\text{Yb}$ -DTPA remaining (mCi)	Activity remaining (%)
0803	Delayed flow over convexities	9	1.007	0.028	2.80
5917	Delayed flow over convexities	10	1.020	0.009	0.91
0123	Normal	17	1.000	0.007	0.74
6129	Normal	24	1.000	0.011	1.09
3583	Delayed flow over convexities	87	0.935	0.002	0.20

Chicago Pho/Gamma HP) using a 4,000-hole straight bore collimator. To ascertain quantitatively the amount of activity present in the head of each patient, a semi-circular Lucite standard (radius 10 cm, height 2.4 cm), was filled with 0.06 mCi of  $^{169}\text{Yb}$ -DTPA and counted with 3.75 cm of pressed wood between the collimator and head standard. Images obtained from Patient 0803 and the standard are shown for comparison (Fig. 1). Left lateral head counts were obtained for each patient, corrected for room background, and residual activity was determined by comparison with the standard counts (Table 1). The percent of injected activity that remained in the head ranged from 2.8% at 9 days to 0.2% at 87 days following administration (Table 1). These values do not appear "significant" as presented by Barbizet, et al (1).

In a recent study (4), the elimination rate of  $^{169}\text{Yb}$ -DTPA from the CNS following intrathecal administration was comparable to that reported by DeLand (2). Radiation dose estimates have been calculated (4) according to the MIRD method (5), assuming elimination after the last datum point (48 hr following injection) equal to the physical decay rate of  $^{169}\text{Yb}$  (the most conservative assumption). In patients with delayed cerebrospinal fluid flow, the most conservative dosimetry assumptions yield surface CNS doses in the order of 30 rads (for 500  $\mu\text{Ci}$  of  $^{169}\text{Yb}$ -DTPA).

Central nervous system clearance of  $^{169}\text{Yb}$ -DTPA is similar to that obtained with  $^{131}\text{I}$ -IHSA (6) and postinjection aseptic meningitis has not been encountered. Our findings based on data obtained from both humans and animals indicate that  $^{169}\text{Yb}$ -DTPA is a safe radiopharmaceutical for cisternographic use and can be recommended for these studies.

#### STANDARD TECHNIQUES FOR THE MEASUREMENT OF RED CELL AND PLASMA VOLUME

The expert panel on the Diagnostic Applications of Radioisotopes in Hematology which was established by the International Committee for Standardization in Hematology has prepared a document which deals with the technical and analytical aspects




FIG. 1. Scintiphotos of lateral head standard containing 0.06 mCi  $^{169}\text{Yb}$ -DTPA and lateral view of patient 0803 imaged 9 days following intrathecal injection of 1.0 mCi  $^{169}\text{Yb}$ -DTPA.

RICHARD L. MORIN  
FRANK H. DeLAND  
Veterans Administration Hospital and  
University of Florida,  
College of Medicine  
Gainesville, Florida

#### REFERENCES

1. BARBIZET J, DUIZABO P, THOMAS J, et al: Danger of ytterbium-DTPA in isotopic cisternography and ventriculography. *Nouv Presse Med* 1: 2899-2901, 1972
2. DeLAND FH: Biological behavior of  $^{169}\text{Yb}$ -DTPA after intrathecal administration. *J Nucl Med* 14: 93-98, 1973
3. WAGNER HN, HOSAIN F, DeLAND FH, et al: A new radiopharmaceutical for cisternography—chelated ytterbium-169. *Radiology* 95: 121-125, 1970
4. MORIN RL, BROOKEMAN VA:  $^{169}\text{Yb}$ -DTPA distribution and dosimetry in cisternography: to be published
5. LOEVINGER R, BERMAN M: A schema for absorbed-dose calculations for biologically distributed radionuclides. MIRD Pamphlet No 1, *J Nucl Med* 9:Suppl No 1, 7-14, 1968
6. HARBERT JC, REED V, McCULLOUGH DC: Comparison between  $^{131}\text{I}$ -IHSA and  $^{169}\text{Yb}$ -DTPA for cisternography. *J Nucl Med* 14: 765-768, 1973